Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05703269 · ClinicalTrials.gov registry record · NA

Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy

A NA study of Non-Small Cell Lung Cancer and Melanoma, sponsored by Wake Forest University Health Sciences.

Recruiting
Registry status
NA
Development phase
244
Enrollment target
20
Study locations

NCT05703269 is a NA study of Non-Small Cell Lung Cancer and Melanoma that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 244 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05703269, a NA study of Non-Small Cell Lung Cancer and Melanoma, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.

RECRUITING
Registry status
NA
Development phase
244 participants
Enrollment target
20
Study locations

Study Summary

This study is designed to see if we can lower the chance of side effects from radiation in patients with breast, kidney, small cell lung cancer, non-small cell lung cancer or melanoma that has spread to the brain and who are also being treated with immunotherapy, specifically immune checkpoint inhibitor (ICI) therapy. This study will compare the usual care treatment of single fraction stereotactic radiosurgery (SSRS) given on one day versus fractionated stereotactic radiosurgery (FSRS), which is a lower dose of radiation given over a few days to determine if FSRS is better or worse at reducing side effects than usual care treatment.

Interventions

  • RADIATION single fraction stereotactic radiosurgery (SSRS)
  • RADIATION fractionated stereotactic radiosurgery (FSRS)

Study Locations (20)

Michigan

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor - Ann Arbor
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton - Brighton
  • Genesys Hurley Cancer Institute - Flint
  • Trinity Health Saint Mary Mercy Livonia Hospital - Livonia
  • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus - Ypsilanti

Illinois

  • Decatur Memorial Hospital - Decatur
  • Crossroads Cancer Center - Effingham
  • HSHS Saint Elizabeth's Hospital - O'Fallon
  • OSF Saint Francis Medical Center - Peoria

New York

  • Montefiore Medical Center-Einstein Campus - The Bronx
  • Montefiore Medical Center-Weiler Hospital - The Bronx
  • Montefiore Medical Center - Moses Campus - The Bronx

Missouri

  • Mercy Hospital Springfield - Springfield
  • Mercy Hospital South - St Louis

New Mexico

  • Lovelace Medical Center-Saint Joseph Square - Albuquerque
  • Lovelace Radiation Oncology - Albuquerque

North Carolina

  • Carolinas Medical Center/Levine Cancer Institute - Charlotte
  • Atrium Health Cabarrus/LCI-Concord - Concord

Georgia

  • Lewis Cancer and Research Pavilion at Saint Joseph's/Candler - Savannah

New Jersey

  • Overlook Medical Center - Summit

Trial Details

FieldValue
Enrollment Target 244 participants
Start Date 2023-07-11
Est. Completion 2028-03-31
Phase NA

Sponsor

Wake Forest University Health Sciences

1,140 total trials

What the Registry Record Tells You About NCT05703269

The ClinicalTrials.gov registry entry for NCT05703269 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 244 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (63% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which single fraction stereotactic radiosurgery (SSRS) is the first listed.

NCT05703269 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Michigan, Illinois, New York.

Frequently Asked Questions

What is clinical trial NCT05703269 about?

NCT05703269 is a clinical study titled "Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy". This study is designed to see if we can lower the chance of side effects from radiation in patients with breast, kidney, small cell lung cancer, non-small cell lung cancer or melanoma that has spread to the brain and who are also being treated with immunotherapy, specifically immune checkpoint inhib...

What is the current status of trial NCT05703269?

This trial is currently recruiting. It is a NA study. The enrollment target is 244 participants. The study started on 2023-07-11. Estimated completion is 2028-03-31.

What conditions does trial NCT05703269 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma, Breast Carcinoma, Small-cell Lung Cancer.

What interventions are being tested in trial NCT05703269?

The interventions under investigation include: single fraction stereotactic radiosurgery (SSRS) (RADIATION), fractionated stereotactic radiosurgery (FSRS) (RADIATION).

Who is sponsoring clinical trial NCT05703269?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05703269 being conducted?

This trial has 20 study locations across Georgia, Illinois, Michigan, Missouri, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.